• Search History (Register)
  • MeSH Browser
Sort by Relevance
Search Results [27 Hits] Selected Records [0 Hits] [Clear]
Year Source Title
2024 National Institute for Health and Care Excellence (NICE) Zanubrutinib with obinutuzumab for treating relapsed or refractory B-cell follicular lymphoma after 2 or more treatments (terminated appraisal). NICE technology appraisal guidance 978
2021 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Obinutuzumab (chronic lymphocytic leukaemia) - Benefit assessment according to §35a Social Code Book V]
2021 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Obinutuzumab (follicular lymphoma, after rituximab) - Benefit assessment according to §35a Social Code Book V]
2021 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Obinutuzumab (follicular lymphoma, first line) - Benefit assessment according to §35a Social Code Book V]
2021 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Acalabrutinib (chronic lymphocytic leukaemia; combination with obinutuzumab) - Benefit assessment according to §35a Social Code Book V]
2021 National Institute for Health and Care Excellence (NICE) Ibrutinib with obinutuzumab for untreated chronic lymphocytic leukaemia and small lymphocytic lymphoma (terminated appraisal). NICE technology appraisal guidance 702
2021 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Acalabrutinib (previously untreated chronic lymphocytic leukaemia; combination with obinutuzumab) - Second Addendum to Commission A20-104]
2021 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Acalabrutinib (previously untreated chronic lymphocytic leukaemia; combination with obinutuzumab) - Addendum to Commission A20-104]
2020 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Venetoclax (chronic lymphocytic leukaemia) - Benefit assessment according to §35a Social Code Book V]
2020 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Venetoclax (chronic lymphocytic leukaemia) - Addendum to Commission A20-39]
2020 National Institute for Health and Care Excellence (NICE) Obinutuzumab with bendamustine for treating follicular lymphoma after rituximab. NICE technology appraisal guidance 629
2020 The National Health Care Institute (ZIN, Zorginstituut Nederland) Package advice venetoclax (Venclyxto®) in combination with obinutuzumab for the treatment of adult patients with previously untreated chronic lymphatic leukaemia (CLL)
2020 National Institute for Health and Care Excellence (NICE) Venetoclax with obinutuzumab for untreated chronic lymphocytic leukaemia. NICE technology appraisal guidance 663
2020 The Federal Joint Committee (G-BA) [Pharmaceutical Directive/Annex XII: Polatuzumab Vedotin (Diffuse Large B-Cell Lymphoma, Combination with Bendamustine and Rituximab)]
2020 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Ibrutinib (new therapeutic indication, chronic lymphocytic leukaemia) - Benefit assessment according to §35a Social Code Book V]
2018 National Institute for Health and Care Excellence (NICE) Obinutuzumab for untreated advanced follicular lymphoma. NICE technology appraisal guidance 513
2018 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Obinutuzumab (non-pretreated advanced follicular lymphoma) - Assessment according to §35a (1), Sentence 11, Social Code Book V]
2016 NIHR Horizon Scanning Centre (NIHR HSC) Obinutuzumab (Gazyvaro) with bendamustine for chronic lymphocytic leukaemia ─ first line
2016 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Obinutuzumab - Assessment according to §35a (para. 1., sentence 10) Social Code Book V]
2016 Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI-HTA) Obinutuzumab (Gazyvaro®) in combination with bendamustine for the treatment of relapsed/refractory follicular lymphoma (FL)
2015 National Institute for Health and Care Excellence (NICE) Obinutuzumab in combination with chlorambucil for untreated chronic lymphocytic leukaemia. NICE technology appraisal guidance 343
2015 NIHR Horizon Scanning Centre (NIHR HSC) Obinutuzumab (Gazyvaro) for indolent non-Hodgkin lymphoma – first line, in combination with chemotherapy
2014 NIHR Horizon Scanning Centre (NIHR HSC) Obinutuzumab in combination with CHOP chemotherapy for CD20-positive diffuse large B-cell lymphoma – first line
2014 NIHR Horizon Scanning Centre (NIHR HSC) Obinutuzumab in combination with bendamustine for rituximab-refractory indolent non-Hodgkin's lymphoma – second line
2014 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Obinituzumab - Assessment according to § 35a (para. 1, sentence 10) Social Code Book V (dossier assessment)]
2014 Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI-HTA) Obinutuzumab (Gazyva®) for previously untreated patients with chronic lymphocytic leukaemia (CLL)
2012 NIHR Horizon Scanning Centre (NIHR HSC) Obinutuzumab with chlorambucil for chronic lymphocytic leukaemia– first line